The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding ...

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of ...

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer ...

SMART combines high-dose IMRT with extrapleural pneumonectomy, showing improved survival for malignant pleural mesothelioma patients. The trial demonstrated a median overall survival of 24.4 months, ...

Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery ...

The MARS2 trial put the mesothelioma treatment community off its axis, at least in terms of whether these patients should undergo surgery. The phase III study showed that extended pleurectomy ...

Researchers have developed a new method for filling and sealing pleural cavities. The process consists of injecting polyurethane foams into the lungs with a self-expanding and self-modelling capacity ...

Please provide your email address to receive an email when new articles are posted on . Previous studies investigated whether surgery may extend survival among patients with malignant pleural ...

The excessive buildup of fluid in the space between your lungs and chest cavity, known as water fluid is also called Pleural effusion. The condition in which both the lungs get affected is called ...

IRVINE, Calif.--(BUSINESS WIRE)--ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results presented at the 2020 Virtual Program of the ...

The median survival of patients undergoing trimodality therapy is 1–2 years, but some patients (19%) can live for 3–14 years. To improve outcomes and survival, the focus of clinical research over the ...